Immunosuppression-Independent Role of Regulatory T Cells against Hypertension-Driven Renal Dysfunctions

REFERENCES

• Josefowicz SZ, Lu LF, Rudensky AY. 2012. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 30:531–564. http://dx.doi.org/10.1146/annurev.immunol.25.022106.141623.
   PubMed Web of Science ®Google Scholar
• Shevach EM. 2009. Mechanisms of Foxp3+ T regulatory cell-mediated suppression. Immunity 30:636–645. http://dx.doi.org/10.1016/j.immuni.2009.04.010.
   PubMed Web of Science ®Google Scholar
• Burzyn D, Benoist C, Mathis D. 2013. Regulatory T cells in nonlymphoid tissues. Nat Immunol 14:1007–1013. http://dx.doi.org/10.1038/ni.2683.
   PubMed Web of Science ®Google Scholar
• Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, Sefik E, Tan TG, Wagers AJ, Benoist C, Mathis D. 2013. A special population of regulatory T cells potentiates muscle repair. Cell 155:1282–1295. http://dx.doi.org/10.1016/j.cell.2013.10.054.
   PubMed Web of Science ®Google Scholar
• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365:217–223. http://dx.doi.org/10.1016/S0140-6736(05)70151-3.
   PubMed Web of Science ®Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. 2006. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757. http://dx.doi.org/10.1016/S0140-6736(06)68770-9.
   PubMed Web of Science ®Google Scholar
• Liu Y. 2011. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 7:684–696. http://dx.doi.org/10.1038/nrneph.2011.149.
   PubMed Web of Science ®Google Scholar
• Wynn TA, Ramalingam TR. 2012. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 18:1028–1040. http://dx.doi.org/10.1038/nm.2807.
   PubMed Web of Science ®Google Scholar
• Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, Rahn HP, Plehm R, Wellner M, Elitok S, Gratze P, Dechend R, Luft FC, Muller DN. 2009. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation 119:2904–2912. http://dx.doi.org/10.1161/CIRCULATIONAHA.108.832782.
   PubMed Web of Science ®Google Scholar
• Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. 2011. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 57:469–476. http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.162941.
   PubMed Web of Science ®Google Scholar
• Kasal DA, Barhoumi T, Li MW, Yamamoto N, Zdanovich E, Rehman A, Neves MF, Laurant P, Paradis P, Schiffrin EL. 2012. T regulatory lymphocytes prevent aldosterone-induced vascular injury. Hypertension 59:324–330. http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.181123.
   PubMedGoogle Scholar
• Muller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, Fiebeler A, Ju X, Finckenberg P, Theuer J, Viedt C, Kreuzer J, Heidecke H, Haller H, Zenke M, Luft FC. 2002. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 161:1679–1693. http://dx.doi.org/10.1016/S0002-9440(10)64445-8.
   PubMed Web of Science ®Google Scholar
• Crowley SD, Frey CW, Gould SK, Griffiths R, Ruiz P, Burchette JL, Howell DN, Makhanova N, Yan M, Kim HS, Tharaux PL, Coffman TM. 2008. Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol 295:F515–F524. http://dx.doi.org/10.1152/ajprenal.00527.2007.
   PubMedGoogle Scholar
• Mervaala E, Muller DN, Park JK, Dechend R, Schmidt F, Fiebeler A, Bieringer M, Breu V, Ganten D, Haller H, Luft FC. 2000. Cyclosporin A protects against angiotensin II-induced end-organ damage in double transgenic rats harboring human renin and angiotensinogen genes. Hypertension 35:360–366. http://dx.doi.org/10.1161/01.HYP.35.1.360.
   PubMedGoogle Scholar
• Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. 2007. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 204:2449–2460. http://dx.doi.org/10.1084/jem.20070657.
   PubMed Web of Science ®Google Scholar
• Madhur MS, Lob HE, McCann LA, Iwakura Y, Blinder Y, Guzik TJ, Harrison DG. 2010. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension 55:500–507. http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.145094.
   PubMed Web of Science ®Google Scholar
• Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K, Fujita T. 2003. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 42:31–38. http://dx.doi.org/10.1161/01.HYP.0000075082.06183.4E.
   PubMed Web of Science ®Google Scholar
• Crowley SD, Song YS, Lin EE, Griffiths R, Kim HS, Ruiz P. 2010. Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 298:R1089–R1097. http://dx.doi.org/10.1152/ajpregu.00373.2009.
   PubMed Web of Science ®Google Scholar
• Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, Vinh A, Weyand CM. 2011. Inflammation, immunity, and hypertension. Hypertension 57:132–140. http://dx.doi.org/10.1161/HYPERTENSIONAHA.110.163576.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Iturbe B, Pons H, Herrera-Acosta J, Johnson RJ. 2001. Role of immunocompetent cells in nonimmune renal diseases. Kidney Int 59:1626–1640. http://dx.doi.org/10.1046/j.1523-1755.2001.0590051626.x.
   PubMed Web of Science ®Google Scholar
• Rodríguez-Iturbe B, Pons H, Quiroz Y, Gordon K, Rincon J, Chavez M, Parra G, Herrera-Acosta J, Gomez-Garre D, Largo R, Egido J, Johnson RJ. 2001. Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59:2222–2232. http://dx.doi.org/10.1046/j.1523-1755.2001.00737.x.
   PubMed Web of Science ®Google Scholar
• McMaster WG, Kirabo A, Madhur MS, Harrison DG. 2015. Inflammation, immunity, and hypertensive end-organ damage. Circ Res 116:1022–1033. http://dx.doi.org/10.1161/CIRCRESAHA.116.303697.
   PubMed Web of Science ®Google Scholar
• Bustelo XR. 2000. Regulatory and signaling properties of the Vav family. Mol Cell Biol 20:1461–1477. http://dx.doi.org/10.1128/MCB.20.5.1461-1477.2000.
   PubMed Web of Science ®Google Scholar
• Bustelo XR. 2014. Vav family exchange factors: an integrated regulatory and functional view. Small GTPases 5(2):9. http://dx.doi.org/10.4161/21541248.2014.973757.
   PubMedGoogle Scholar
• Turner M, Billadeau DD. 2002. VAV proteins as signal integrators for multi-subunit immune-recognition receptors. Nat Rev Immunol 2:476–486. http://dx.doi.org/10.1038/nri840.
   PubMed Web of Science ®Google Scholar
• Tarakhovsky A, Turner M, Schaal S, Mee PJ, Duddy LP, Rajewsky K, Tybulewicz VL. 1995. Defective antigen receptor-mediated proliferation of B and T cells in the absence of Vav. Nature 374:467–470. http://dx.doi.org/10.1038/374467a0.
   PubMed Web of Science ®Google Scholar
• Turner M, Mee PJ, Walters AE, Quinn ME, Mellor AL, Zamoyska R, Tybulewicz VL. 1997. A requirement for the Rho-family GTP exchange factor Vav in positive and negative selection of thymocytes. Immunity 7:451–460. http://dx.doi.org/10.1016/S1074-7613(00)80367-2.
   PubMed Web of Science ®Google Scholar
• Fujikawa K, Miletic AV, Alt FW, Faccio R, Brown T, Hoog J, Fredericks J, Nishi S, Mildiner S, Moores SL, Brugge J, Rosen FS, Swat W. 2003. Vav1/2/3-null mice define an essential role for Vav family proteins in lymphocyte development and activation but a differential requirement in MAPK signaling in T and B cells. J Exp Med 198:1595–1608. http://dx.doi.org/10.1084/jem.20030874.
   PubMed Web of Science ®Google Scholar
• Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, Lopez-Novoa JM, Bustelo XR. 2006. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med 12:841–845. http://dx.doi.org/10.1038/nm1426.
   PubMedGoogle Scholar
• Sauzeau V, Jerkic M, Lopez-Novoa JM, Bustelo XR. 2007. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell 18:943–952. http://dx.doi.org/10.1091/mbc.E06-09-0877.
   PubMedGoogle Scholar
• Sauzeau V, Horta-Junior JAC, Riolobos AS, Fernandez G, Sevilla MA, Lopez DE, Montero MJ, Rico B, Bustelo XR. 2010. Vav3 is involved in GABAergic axon guidance events important for the proper function of brainstem neurons controlling cardiovascular, respiratory, and renal parameters. Mol Biol Cell 21:4251–4263. http://dx.doi.org/10.1091/mbc.E10-07-0639.
   PubMedGoogle Scholar
• Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. 2010. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest 120:315–330. http://dx.doi.org/10.1172/JCI38356.
   PubMed Web of Science ®Google Scholar
• Jonsson CA, Svensson L, Carlsten H. 1999. Beneficial effect of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil on survival and severity of glomerulonephritis in systemic lupus erythematosus (SLE)-prone MRLlpr/lpr mice. Clin Exp Immunol 116:534–541. http://dx.doi.org/10.1046/j.1365-2249.1999.00901.x.
   PubMed Web of Science ®Google Scholar
• Kassan M, Montero MJ, Sevilla MA. 2010. In vitro antioxidant activity of pravastatin provides vascular protection. Eur J Pharmacol 630:107–111. http://dx.doi.org/10.1016/j.ejphar.2009.12.037.
   PubMedGoogle Scholar
• Menacho-Márquez M, Garcia-Escudero R, Ojeda V, Abad A, Delgado P, Costa C, Ruiz S, Alarcon B, Paramio JM, Bustelo XR. 2013. The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops. PLoS Biol 11:e1001615. http://dx.doi.org/10.1371/journal.pbio.1001615.
   PubMedGoogle Scholar
• Paragas N, Qiu A, Hollmen M, Nickolas TL, Devarajan P, Barasch J. 2012. NGAL-Siderocalin in kidney disease. Biochim Biophys Acta 1823:1451–1458. http://dx.doi.org/10.1016/j.bbamcr.2012.06.014.
   PubMedGoogle Scholar
• Benigni A, Cassis P, Remuzzi G. 2010. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2:247–257. http://dx.doi.org/10.1002/emmm.201000080.
   PubMed Web of Science ®Google Scholar
• Rees DD, Palmer RM, Hodson HF, Moncada S. 1989. A specific inhibitor of nitric oxide formation from l-arginine attenuates endothelium-dependent relaxation. Br J Pharmacol 96:418–424. http://dx.doi.org/10.1111/j.1476-5381.1989.tb11833.x.
   PubMed Web of Science ®Google Scholar
• Sintchak MD, Nimmesgern E. 2000. The structure of inosine 5′-monophosphate dehydrogenase and the design of novel inhibitors. Immunopharmacology 47:163–184. http://dx.doi.org/10.1016/S0162-3109(00)00193-4.
   PubMed Web of Science ®Google Scholar
• D'Alessio FR, Tsushima K, Aggarwal NR, West EE, Willett MH, Britos MF, Pipeling MR, Brower RG, Tuder RM, McDyer JF, King LS. 2009. CD4+ CD25+ Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J Clin Invest 119:2898–2913. http://dx.doi.org/10.1172/JCI36498.
   PubMed Web of Science ®Google Scholar
• Lewkowicz P, Lewkowicz N, Sasiak A, Tchorzewski H. 2006. Lipopolysaccharide-activated CD4+ CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 177:7155–7163. http://dx.doi.org/10.4049/jimmunol.177.10.7155.
   PubMed Web of Science ®Google Scholar
• Junger WG. 2011. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11:201–212. http://dx.doi.org/10.1038/nri2938.
   PubMed Web of Science ®Google Scholar
• Noris M, Casiraghi F, Todeschini M, Cravedi P, Cugini D, Monteferrante G, Aiello S, Cassis L, Gotti E, Gaspari F, Cattaneo D, Perico N, Remuzzi G. 2007. Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol 18:1007–1018. http://dx.doi.org/10.1681/ASN.2006101143.
   PubMed Web of Science ®Google Scholar
• Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O'Garra A. 2002. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 195:603–616. http://dx.doi.org/10.1084/jem.20011629.
   PubMed Web of Science ®Google Scholar
• Hafiz MM, Faradji RN, Froud T, Pileggi A, Baidal DA, Cure P, Ponte G, Poggioli R, Cornejo A, Messinger S, Ricordi C, Alejandro R. 2005. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 80:1718–1728. http://dx.doi.org/10.1097/01.tp.0000187881.97068.77.
   PubMed Web of Science ®Google Scholar
• Banerjee R, Halil O, Bain BJ, Cummins D, Banner NR. 2000. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 70:1608–1610. http://dx.doi.org/10.1097/00007890-200012150-00012.
   PubMed Web of Science ®Google Scholar
• Nogueras F, Espinosa MD, Mansilla A, Torres JT, Cabrera MA, Martin-Vivaldi R. 2005. Mycophenolate mofetil-induced neutropenia in liver transplantation. Transplant Proc 37:1509–1511. http://dx.doi.org/10.1016/j.transproceed.2005.02.038.
   PubMed Web of Science ®Google Scholar
• Cowley AW, Jr. 1992. Long-term control of arterial blood pressure. Physiol Rev 72:231–300.
   PubMed Web of Science ®Google Scholar
• Hwang S, Song KD, Lesourne R, Lee J, Pinkhasov J, Li L, El-Khoury D, Love PE. 2012. Reduced TCR signaling potential impairs negative selection but does not result in autoimmune disease. J Exp Med 209:1781–1795. http://dx.doi.org/10.1084/jem.20120058.
   PubMedGoogle Scholar
• Ruiz S, Santos E, Bustelo XR. 2009. The use of knockout mice reveals a synergistic role of the Vav1 and Rasgrf2 gene deficiencies in lymphomagenesis and metastasis. PLoS One 4:e8229. http://dx.doi.org/10.1371/journal.pone.0008229.
   PubMed Web of Science ®Google Scholar
• Sommers CL, Lee J, Steiner KL, Gurson JM, Depersis CL, El-Khoury D, Fuller CL, Shores EW, Love PE, Samelson LE. 2005. Mutation of the phospholipase C-γ1-binding site of LAT affects both positive and negative thymocyte selection. J Exp Med 201:1125–1134. http://dx.doi.org/10.1084/jem.20041869.
   PubMed Web of Science ®Google Scholar
• Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, Sakihama T, Matsutani T, Negishi I, Nakatsuru S, Sakaguchi S. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature 426:454–460. http://dx.doi.org/10.1038/nature02119.
   PubMed Web of Science ®Google Scholar
• Pan D, Amison RT, Riffo-Vasquez Y, Spina D, Cleary SJ, Wakelam MJ, Page CP, Pitchford SC, Welch HC. 2015. P-Rex and Vav Rac-GEFs in platelets control leukocyte recruitment to sites of inflammation. Blood 125:1146–1158. http://dx.doi.org/10.1182/blood-2014-07-591040.
   PubMed Web of Science ®Google Scholar
• Lawson CD, Donald S, Anderson KE, Patton DT, Welch HC. 2011. P-Rex1 and Vav1 cooperate in the regulation of formyl-methionyl-leucyl-phenylalanine-dependent neutrophil responses. J Immunol 186:1467–1476. http://dx.doi.org/10.4049/jimmunol.1002738.
   PubMed Web of Science ®Google Scholar